Primary heptocellular carcinoma
Conditions
Interventions
Group A :Opioid
Group B:Parecoxib
Sponsors
The Afiliated Tumor Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male and female aged 18 to 75 years, without understanding disorders, prepared to be treated by TACE; 2. Signed informed consent; 3. ECOG =2.
Exclusion criteria
Exclusion criteria: Those patients were excluded with abnormal preoperativ tests, including liver and kidney function, blood coagulation anomaly et al, Serious drug allergy history or sulfonamide drug allergy, hypertension or diabetes mellitus, ulcer history or gastrointestinal tract hemorrhage history, inflammatory bowel disease, NSAIDS or opioids intake in three months, serious trauma, infection and heart cerebrovascular disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life;VAS;Drug adverse reactions ;Liver function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body temperature;Postoperative hospital stay ;Patient satisfaction with nursing care ; | — |
Countries
China
Contacts
Public ContactXiaojuan Jiang
The Afiliated Tumor Hospital of Xinjiang Medical University
Outcome results
None listed